Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study-Reference-Cited by-同舟云学术

Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study

Published:2021-11 Issue:11 Volume:19 Page:2324-2332.e6
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Danese Silvio^ORCID,Klopocka Maria,Scherl Ellen J.,Romatowski Jacek,Allegretti Jessica R.,Peeva Elena,Vincent Michael S.,Schoenbeck Uwe,Ye Zhan,Hassan-Zahraee Mina,Rath Natalie,Li Gang,Neelakantan Srividya,Banfield Christopher,Lepsy Christopher,Chandra Deepa E.,Hung Kenneth E.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference36 articles.

1. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis;Feuerstein;Gastroenterology,2020

2. ACG clinical guideline: ulcerative colitis in adults;Rubin;Am J Gastroenterol,2019

3. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis;Singh;Aliment Pharmacol Ther,2018

4. A [glyco]biomarker that predicts failure to standard therapy in ulcerative colitis patients;Pereira;J Crohns Colitis,2019

5. ACG clinical guideline: management of Crohn’s disease in adults;Lichtenstein;Am J Gastroenterol,2018

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD;Gut;2024-09-11

2. Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments;Trends in Pharmacological Sciences;2024-09

3. Anti-TL1A monoclonal antibody modulates the dysregulation of Th1/Th17 cells and attenuates granuloma formation in sarcoidosis by inhibiting the PI3K/AKT signaling pathway;International Immunopharmacology;2024-08

4. Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8⁺T cells and inhibited tumor growth;Journal for ImmunoTherapy of Cancer;2024-08

5. RIPK3 and caspase-8 interpret cytokine signals to regulate ILC3 survival in the gut;Mucosal Immunology;2024-08